Barclays analyst Gena Wang raised the firm’s price target on BioCryst to $7 from $6 and keeps an Equal Weight rating on the shares. The analyst says Orladeyo Q2 revenue beat estimates and the 2024 revenue guidance was raised. BioCryst’s earlier-stage pipeline is advancing, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Clarifies Recent Report’s Regulatory Significance
- BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
- BCRX Earnings this Week: How Will it Perform?
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst to Report Second Quarter 2024 Financial Results on August 5